Survodutide (BI 456906): the GLP-1 / glucagon dual agonist and its Phase 2 data

Survodutide (development code BI 456906) is one of the more interesting molecules in the incretin pipeline because of what its second receptor does. Where semaglutide acts on the GLP-1 pathway alone, survodutide is a dual agonist of the GLP-1 receptor and the glucagon receptor. It is being developed jointly by Boehringer Ingelheim and Zealand Pharma, and it is investigational — not approved for any use, anywhere. Here is a straight read of the two Phase 2 trials that define what we actually know.

What it is, and why the glucagon arm matters

Survodutide is a once-weekly subcutaneous peptide. The GLP-1 component does the familiar work: suppressing appetite and improving glycemic control. The distinctive piece is glucagon-receptor agonism. Glucagon, at these signaling levels, is thought to raise energy expenditure and promote mobilization of fat from the liver — so the design intent is to combine reduced calorie intake (GLP-1) with increased calorie burn and direct hepatic fat handling (glucagon). That mechanistic logic is also why survodutide has been tested not just for weight but specifically for liver disease.

It helps to place survodutide on the map of multi-receptor agonists. Tirzepatide pairs GLP-1 with GIP rather than glucagon (covered in our tirzepatide versus semaglutide comparison), while retatrutide goes further still, hitting GIP, GLP-1 and glucagon all at once — see our retatrutide Phase 2 evidence. Survodutide sits between them: two receptors, one of which is glucagon.

The Phase 2 obesity trial

In a 46-week, randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial across 43 centers, 387 adults with obesity (BMI ≥27, without diabetes) were assigned to survodutide at 0.6, 2.4, 3.6 or 4.8 mg or placebo, once weekly.^[1] At week 46, mean body-weight change was dose-dependent: about −14.9% at the top 4.8 mg dose, versus about −2.8% with placebo (with intermediate doses landing near −12.5% and −13.2%).^[1]

Those magnitudes are broadly in the same territory as GLP-1 monotherapy and dual GIP/GLP-1 therapy, though cross-trial comparison is only suggestive. As with every incretin agent, the weight benefit comes partly from reduced lean mass as well as fat — a caveat we cover in GLP-1 and lean-mass loss. The obesity trial was not powered to settle that or long-term outcomes; it was a dose-finding study.

The Phase 2 MASH / liver trial

The liver trial is where survodutide's glucagon arm was most directly tested. In a 48-week Phase 2 trial, 293 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage F1–F3 were randomized to survodutide 2.4, 4.8 or 6.0 mg or placebo.^[2]The primary endpoint — histologic improvement in MASH with no worsening of fibrosis — was met by 47%, 62% and 43% of participants across the three doses, versus 14% on placebo.^[2]

Secondary readouts pointed the same direction: a decrease in liver fat content of at least 30% occurred in 63%, 67% and 57% of survodutide participants versus 14% on placebo, and improvement in fibrosis by at least one stage occurred in 34%, 36% and 34% versus 22% on placebo.^[2] The authors concluded survodutide was superior to placebo for MASH improvement without worsening fibrosis, and that the result warranted Phase 3 investigation.^[2]

The honest caveats

Two things deserve emphasis. First, tolerability: gastrointestinal side effects were common and dose-related. In the MASH trial, nausea (66% vs 23%), diarrhea (49% vs 23%) and vomiting (41% vs 4%) were all more frequent with survodutide than placebo, and serious adverse events occurred in 8% versus 7%.^[2] The obesity trial reported the same GI-dominant pattern.^[1]Second, and most important: survodutide is not approved anywhere. Both trials are mid-stage, dose-finding human RCTs — good evidence of a real effect, but not the large, long, outcome-powered studies that approval requires. Phase 3 programs, including a 76-week obesity efficacy and safety trial, are ongoing.^[3]

The honest bottom line

Survodutide is a genuinely dual-mechanism drug whose glucagon arm shows up in two ways: competitive weight loss and, more distinctively, strong Phase 2 MASH results. That combination is what makes it worth watching alongside other next-generation candidates such as oral orforglipron. But the honest label remains “promising Phase 2” — not approved, no long-term outcomes, and a glucagon component whose full safety picture is exactly what Phase 3 exists to establish. For now, that is the correct and limited claim.